Evidence map›Paper›PMID 42179346›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2026

A multiplexed, systems-based approach for prediction of antibody neutralization breadth for soluble human receptors.

Qixin Wang, Lindsay R McManus, Kate S Levine, Ross Blanc, Hadar Malca, Brian A Joughin, Caihong Bi, Keerti, Douglas A Lauffenburger, Duane R Wesemann and 1 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qixin WangDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Lindsay R McManusDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Kate S LevineDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Ross BlancDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Hadar MalcaDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Brian A JoughinDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States.ORCID 0000-0003-1022-9450
Caihong BiDivision of Allergy and Immunology, Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
KeertiDivision of Allergy and Immunology, Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States.ORCID 0000-0002-0050-989X
Duane R WesemannDivision of Allergy and Immunology, Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.ORCID 0000-0002-6690-944X
Ryan P McNamaraDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States.ORCID 0000-0002-8866-3532

Funding

Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Kristian Graugaard Andersen · 2018 to 2026
$32.0M
Technology and Computational CoreP01AI165072 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI WESEMANN, DUANE R. · 2021 to 2023
$19.6M
A systems immunology approach to evaluate malaria vaccine performance in endemic regions of KenyaU01AI165524 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANN M MOORMANN · 2022 to 2026
$4.9M
Antibody Durability DynamicsR01AI170715 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Duane R. Wesemann · 2022 to 2026
$3.4M
Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic DiseasesR01AR080659 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Jeffrey Andrew Sparks · 2023 to 2026
$2.9M
NIAID NIH HHS P01 AI165072NIAID NIH HHS R01 AI170715NIAID NIH HHS U01 AI165524NIAID NIH HHS U19 AI135995NIAID NIH HHS UM1 AI164566NIAMS NIH HHS R01 AR080659NIH HHS P01AI165072NIH HHS R01AI170715NIH HHS R01AR080659NIH HHS U01AI165524NIH HHS U19AI135995NIH HHS UM1AI164566
6 · The paper itself

Abstract

For endemically circulating viruses, quantifying neutralization capacity of antibodies in a rapid and high-throughput manner is paramount given the ever-evolving targets of neutralization. Moreover, identifying features of an antibody response correlating with neutralization at the multivariate level can inform vaccine boosting strategies and next-generation monoclonal antibody therapies. In this study, we developed a systems-predicted neutralizing antibody platform that is capable of quantifying neutralization capacity at the multiplex level. We validated the platform using SARS-CoV-2 ancestral and highly diverged Omicron sublineage spikes simultaneously. Combining these results with a broader systems serology approach identified humoral signatures that predict broadly neutralizing responses that are divergent between vaccine or hybrid immunity. In both cases, though, predicted neutralization responses were enmeshed in antibody networks, showing that target-specific and broadly neutralizing antibody responses are multi-isotype- and subclass-influenced. We propose that neutralization against a diverse array of viral receptor-binding proteins can be quantified using a systems-based platform in a sample- and time-sparing approach, which can be further employed to predict protection against newly emerged viruses or variants.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusHumansNeutralization TestsAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2correlates of protectionFc receptorneutralizationpredictionsystems serology

Identifiers

PMID42179346
PMCPMC13200002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.